200 related articles for article (PubMed ID: 19236220)
1. The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies.
Gupta D; Mani S
Expert Opin Drug Saf; 2009 Jan; 8(1):81-8. PubMed ID: 19236220
[TBL] [Abstract][Full Text] [Related]
2. Novel cytotoxic agents: epothilones.
Goodin S
Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
[TBL] [Abstract][Full Text] [Related]
3. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
4. Ixabepilone, a new treatment option for metastatic breast cancer.
Toppmeyer DL; Goodin S
Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
[TBL] [Abstract][Full Text] [Related]
5. Advances in breast cancer treatment: the emerging role of ixabepilone.
Frye DK
Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882
[TBL] [Abstract][Full Text] [Related]
6. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
7. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues.
Fornier MN
Clin Breast Cancer; 2007 Oct; 7(10):757-63. PubMed ID: 18021476
[TBL] [Abstract][Full Text] [Related]
8. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ixabepilone, a novel epothilone analogue.
Pivot X; Dufresne A; Villanueva C
Clin Breast Cancer; 2007 Apr; 7(7):543-9. PubMed ID: 17509162
[TBL] [Abstract][Full Text] [Related]
11. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with epothilones in patients with breast cancer.
Buzdar AU
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
[TBL] [Abstract][Full Text] [Related]
13. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.
Pronzato P
Drugs; 2008; 68(2):139-46. PubMed ID: 18197722
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
De Luca A; D'Alessio A; Maiello MR; Gallo M; Chicchinelli N; Pergameno M; Piccirilli MS; Normanno N
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1177-85. PubMed ID: 26073581
[TBL] [Abstract][Full Text] [Related]
16. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
17. Application of epothilones in breast cancer therapy.
Cianfrocca M
Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044
[TBL] [Abstract][Full Text] [Related]
18. Ixabepilone: clinical role in metastatic breast cancer.
Denduluri N; Swain S
Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
[TBL] [Abstract][Full Text] [Related]
19. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
Morris PG; Fornier MN
Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
